Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Advanced Cancer
Advanced Malignancies

Interventions: Drug: Cemiplimab
Radiation: Hypofractionated radiotherapy
Drug: Cyclophosphamide
Drug: Docetaxel
Drug: Carboplatin
Drug: GM-CSF
Drug: Paclitaxel
Drug: Pemetrexed

First Posted Date: 2015-03-09

Last Posted Date: 2020-01-27

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 398

Registration Number: NCT02383212

Locations: 🇺🇸
Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 44 locations

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Completed

Conditions: Carcinoma, Non-Squamous Non-Small Cell Lung

Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Drug: Carboplatin
Drug: Nab-Paclitaxel
Drug: Pemetrexed

First Posted Date: 2015-02-20

Last Posted Date: 2021-08-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 723

Registration Number: NCT02367781

Locations: 🇺🇸
University of Miami School of Medicine - Sylvester at Deerfield, Deerfield Beach, Florida, United States
🇺🇸
Fort Wayne Med Oncology & Hematology Inc, Fort Wayne, Indiana, United States
🇺🇸
SCRI Florida Cancer Specialists East, West Palm Beach, Florida, United States

and more 129 locations

Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)

Phase 2

Terminated

Conditions: Mesothelioma, Malignant

Interventions: Drug: Placebo
Drug: Amatuximab
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2015-02-06

Last Posted Date: 2020-03-17

Lead Sponsor: Morphotek

Target Recruit Count: 124

Registration Number: NCT02357147

A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

Phase 1

Completed

Conditions: Malignant Pleural Mesothelioma
Non-Small Cell Lung Cancer

Interventions: Drug: BBI608
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2015-01-28

Last Posted Date: 2022-04-12

Lead Sponsor: Sumitomo Pharma Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT02347917

Locations: 🇯🇵
National Cancer Center Hospital, Tokyo, Japan
🇯🇵
National Cancer Center Hospital East, Chiba, Japan

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Selumetinib
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2015-01-13

Last Posted Date: 2024-03-21

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 62

Registration Number: NCT02337530

Locations: 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
🇨🇦
CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada

and more 9 locations

Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers

Phase 2

Withdrawn

Conditions: Esophagogastric Cancer

Interventions: Drug: Pemetrexed
Drug: Oxaliplatin
Genetic: Germline genotyping analyses for TSER
Drug: Leucovorin
Drug: Fluorouracil

First Posted Date: 2014-11-20

Last Posted Date: 2016-03-08

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT02296671

High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Phase 2

Conditions: Brain Metastases

Interventions: Drug: pemetrexed

First Posted Date: 2014-11-06

Last Posted Date: 2014-11-06

Lead Sponsor: Rongjie Tao

Target Recruit Count: 25

Registration Number: NCT02284490

Locations: 🇨🇳
Neurosurgery, Shandong Cancer Hospital and Institute, Jinan, Shandong, China

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Phase 3

Completed

Conditions: Non-squamous Non-small Cell Lung Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Veliparib
Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2014-10-15

Last Posted Date: 2021-02-26

Lead Sponsor: AbbVie

Target Recruit Count: 595

Registration Number: NCT02264990

Locations: 🇨🇿
Multiscan s.r.o. /ID# 132689, Pardubice, Czechia
🇩🇪
Klinik Loewenstein GmbH /ID# 131925, Löwenstein, Germany
🇹🇷
Inonu University /ID# 136569, Malatya, Turkey

and more 137 locations

A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Nonsquamous Nonsmall Cell Neoplasm of Lung

Interventions: Drug: Pemetrexed
Drug: Carboplatin
Drug: demcizumab

First Posted Date: 2014-10-08

Last Posted Date: 2020-09-09

Lead Sponsor: OncoMed Pharmaceuticals, Inc.

Target Recruit Count: 82

Registration Number: NCT02259582

Locations: 🇧🇪
Centre Hospitalier Jolimont-Lobbes, La Louviere, Belgium
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States

and more 40 locations

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)

Phase 3

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Biological: pembrolizumab
Drug: carboplatin
Drug: paclitaxel
Drug: pemetrexed

First Posted Date: 2014-08-20

Last Posted Date: 2023-10-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1274

Registration Number: NCT02220894

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy